https://www.natera.com/company/news/trifecta-study-demonstrates-prospera-kidney-dd-cfdna-test-outperforms-dsa-in-predicting-antibody-mediated-rejection/
May 10, 2023 - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of the latest data from the Trifecta study in...
trifectastudydemonstrateskidneydd
https://www.qiagen.com/ch/products/discovery-and-translational-research/next-generation-sequencing/dna-sequencing/somatic-panels/qiaseq-targeted-cfdna-ultra
For ultrasensitive targeted next-generation sequencing of cfDNA on Illumina platforms
targetedcfdnaultrapanels
https://www.thermofisher.com/us/en/home/global/forms/transplant-solutions/noninvasive-test-identifying-cfDNA-origin-double-kidney-transplant.html
This on-demand webinar provides an overview of detecting donor-derived cell-free DNA (dd-cfDNA) in patients with two kidney transplants.
minimally invasivetestsupportassigning